The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy

被引：0
|
作者：
Banerjee, S. N.
Thornhill, A.
Evans, D. B.
Littlewood-Evans, A. J.
Dowsett, M.
Martin, L-A
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [21] Modulation of tumor hypoxia in response to treatment with ionizing radiation and the VEGFR-inhibitor PTK787/ZK222584
    Riesterer, O
    Honer, M
    Oehler, C
    Djonov, V
    Bodis, S
    Jochum, W
    Ametamey, S
    Pruschy, M
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S328 - S328
  • [22] Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients
    Jost, Lorenz M.
    Gschwind, Hans-Peter
    Jalava, Tarja
    Wang, Yongyu
    Guenther, Clemens
    Souppart, Claire
    Rottmann, Antje
    Denner, Karsten
    Waldmeier, Felix
    Gross, Gerhard
    Masson, Eric
    Laurent, Dirk
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (11) : 1817 - 1828
  • [23] Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)
    Pavel, M. E.
    Bartel, C.
    Heuck, F.
    Neumann, F.
    Tiling, N.
    Pape, U. F.
    Ploeckinger, U.
    Wiedenmann, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sunil Sharma
    Burgess Freeman
    Jeanette Turner
    James Symanowski
    Phillip Manno
    William Berg
    Nicholas Vogelzang
    Investigational New Drugs, 2009, 27 : 63 - 65
  • [25] Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
    Speca, J. C.
    Mears, A. L.
    Creel, P. A.
    Yenser, S. E.
    Bendell, J. C.
    Morse, M. A.
    Hurwitz, H. I.
    Armstrong, A. J.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme
    Resardon, David
    Friedman, H.
    Brada, M.
    Conrad, C.
    Provenzaie, J.
    Jackson, E.
    Serajuddin, H.
    Chen, B.
    Laurent, D.
    Yung, W.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [27] PTK787/ZK222584 Combined with Interferon Alpha and 5-Fluorouracil Synergistically Inhibits VEGF Signaling Pathway in Hepatocellular Carcinoma
    Katsura, Yoshiteru
    Wada, Hiroshi
    Murakami, Masahiro
    Akita, Hirofumi
    Hama, Naoki
    Kawamoto, Koichi
    Kobayashi, Shogo
    Marubashi, Shigeru
    Eguchi, Hidetoshi
    Tanemura, Masahiro
    Umeshita, Koji
    Doki, Yuichiro
    Mori, Masaki
    Nagano, Hiroaki
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S517 - S526
  • [28] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temazolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
    Reardon, D
    Friedman, H
    Yung, WKA
    Brada, M
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    Laurent, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 110S - 110S
  • [29] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)
    Reardon, D
    Friedman, H
    Brada, N
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    NEURO-ONCOLOGY, 2004, 6 (04) : 381 - 381
  • [30] PTK787/ZK222584 Combined with Interferon Alpha and 5-Fluorouracil Synergistically Inhibits VEGF Signaling Pathway in Hepatocellular Carcinoma
    Yoshiteru Katsura
    Hiroshi Wada
    Masahiro Murakami
    Hirofumi Akita
    Naoki Hama
    Koichi Kawamoto
    Shogo Kobayashi
    Shigeru Marubashi
    Hidetoshi Eguchi
    Masahiro Tanemura
    Koji Umeshita
    Yuichiro Doki
    Masaki Mori
    Hiroaki Nagano
    Annals of Surgical Oncology, 2013, 20 : 517 - 526
12345